IL314832A - Hiv-specific binding molecules and tcr - Google Patents

Hiv-specific binding molecules and tcr

Info

Publication number
IL314832A
IL314832A IL314832A IL31483224A IL314832A IL 314832 A IL314832 A IL 314832A IL 314832 A IL314832 A IL 314832A IL 31483224 A IL31483224 A IL 31483224A IL 314832 A IL314832 A IL 314832A
Authority
IL
Israel
Prior art keywords
seq
specific binding
binding molecule
tcr
alpha
Prior art date
Application number
IL314832A
Other languages
English (en)
Hebrew (he)
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/938,321 external-priority patent/US12103971B2/en
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of IL314832A publication Critical patent/IL314832A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL314832A 2022-02-20 2023-02-20 Hiv-specific binding molecules and tcr IL314832A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263312077P 2022-02-20 2022-02-20
US17/938,321 US12103971B2 (en) 2022-02-20 2022-10-05 HIV specific binding molecules
PCT/EP2023/054236 WO2023156663A1 (en) 2022-02-20 2023-02-20 Hiv-specific binding molecules and tcr

Publications (1)

Publication Number Publication Date
IL314832A true IL314832A (en) 2024-10-01

Family

ID=85321305

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314832A IL314832A (en) 2022-02-20 2023-02-20 Hiv-specific binding molecules and tcr

Country Status (9)

Country Link
US (1) US20250129161A1 (cg-RX-API-DMAC7.html)
EP (1) EP4479423A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508738A (cg-RX-API-DMAC7.html)
KR (1) KR20240149435A (cg-RX-API-DMAC7.html)
AU (1) AU2023222190A1 (cg-RX-API-DMAC7.html)
CA (1) CA3250782A1 (cg-RX-API-DMAC7.html)
IL (1) IL314832A (cg-RX-API-DMAC7.html)
MX (1) MX2024010233A (cg-RX-API-DMAC7.html)
WO (1) WO2023156663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
GB202411647D0 (en) 2024-08-07 2024-09-18 Immunocore Ltd Method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
DK1247095T3 (da) 1999-12-06 2008-12-08 Univ Illinois TCR-proteiner med höj affinitet samt fremgangsmåder
WO2001062908A2 (en) 2000-02-22 2001-08-30 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
EP2048159B1 (en) 2002-11-09 2014-01-01 Immunocore Ltd. T cell receptor display
NZ550815A (en) * 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
GB0506760D0 (en) * 2005-04-01 2005-05-11 Avidex Ltd High affinity HIV TCRS
CN105461802A (zh) * 2005-04-01 2016-04-06 英美偌科有限公司 高亲和力hiv t细胞受体
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
JP7599819B2 (ja) 2016-06-02 2024-12-16 イムノコア リミテッド gp100特異的TCR-抗CD3 scFv融合タンパク質の投薬レジメン
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules

Also Published As

Publication number Publication date
WO2023156663A1 (en) 2023-08-24
CA3250782A1 (en) 2023-08-24
WO2023156663A9 (en) 2024-01-18
EP4479423A1 (en) 2024-12-25
AU2023222190A1 (en) 2024-08-29
MX2024010233A (es) 2024-12-06
US20250129161A1 (en) 2025-04-24
KR20240149435A (ko) 2024-10-14
JP2025508738A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
JP5885220B2 (ja) 高親和性hivt細胞レセプター
HRP20220865T1 (hr) T stanični receptori
FI3433270T3 (fi) T-solureseptoreita
CN105408353A (zh) T细胞受体
RU2018138837A (ru) Т-клеточные рецепторы
CA2516702A1 (en) Modified t cell receptor linked by disulphide bond between constant domain cysteine residues
KR20220087511A (ko) 특이적 결합 분자
US20250129161A1 (en) HIV Specific Binding Molecules and Uses Thereof
CN106336457B (zh) 识别mage‑a3抗原短肽的t细胞受体
CN111662374A (zh) 一种识别afp抗原的高亲和力tcr
JP2025508738A5 (cg-RX-API-DMAC7.html)
CN106459175A (zh) 结合至源自人前胰岛素原(ppi)蛋白的alwgpdpaaa的t细胞受体
CN106478808A (zh) 识别ny-eso-1抗原短肽的t细胞受体
US12103971B2 (en) HIV specific binding molecules
ES2291439T3 (es) Peptidos que presentan una afinidad por la proteina viral gp120, y uso de estos peptidos.
Chen et al. Identification and characterization of a T cell-inducing epitope of bovine ribonuclease that can be restricted by multiple class II molecules
CN113874393B (zh) 对hbv包膜蛋白具有特异性的结合分子
CN119192333A (zh) 一种识别ssx2的t细胞受体及其应用
WO2022022696A1 (zh) 一种识别afp的高亲和力tcr
CN118715240A (zh) Hiv特异性结合分子和tcr
WO2022262842A1 (zh) 一种针对afp抗原的高亲和力t细胞受体
WO2022262835A1 (zh) 一种识别afp抗原的tcr及其编码序列
WO2023005859A1 (zh) 针对抗原ssx2的高亲和力t细胞受体
CN119591693A (zh) 一种识别mage-a4的tcr及其编码序列
RU2022116808A (ru) Т-клеточные рецепторы